Tislelizumab is under clinical development by BeiGene and currently in Pre-Registration for Esophageal Squamous Cell Carcinoma (ESCC).
Major Source of Lupus Morbidity More Common in Certain Racial-Ethnic Groups
Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black